Clinical Trial Update: Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated alternating ixazomib citrate and lenalidomide as maintenance therapy after stem cell transplantation in patients with multiple myeloma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Ninlaro (ixazomib citrate) (ixazomib)
• Revlimid (lenalidomide) (lenalidomide)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Plasma Cell Myeloma, Transplant-Related Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-07-05